Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Carcinoma, Non-Small-Cell Lung 9Esophageal Squamous Cell Carcinoma 5Neoplasm Metastasis 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Recurrence 3Colorectal Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1Sarcoma 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Locally Advanced or Metastatic Urothelial Bladder Cancer 1

Interventions

tislelizumab 4talazoparib 4pembrolizumab 4Docetaxel 4Nivolumab 3PM 01183 2MLN 8237 2Itraconazole 2Fluorouracil 2Cisplatin 2Carboplatin 2zimberelimab 1utomilumab 1urelumab 1ulixertinib 1trifluridine tipiracil drug combination 1sitravatinib 1sapanisertib 1pexidartinib 1pevonedistat 1peposertib 1niraparib 1mogamulizumab 1lenvatinib 1ixabepilone 1eribulin 1durvalumab 1dalotuzumab 1avelumab 1ascrinvacumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Advanced Solid Tumors × tislelizumab × Clear all
NCT04716634 2025-03-25

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

BeiGene

Phase 2 Completed
84 enrolled 17 charts
Other solid neoplasm

Advanced Solid Tumors

NCT03666143 2024-11-04

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

BeiGene

Phase 1 Completed
216 enrolled 20 charts
Other solid neoplasm

Advanced Solid Tumors

NCT03379259 2024-10-26

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

BeiGene

Phase 1/2 Terminated
39 enrolled 29 charts
Other solid neoplasm

Advanced Solid Tumors

NCT04068519 2024-10-26

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

BeiGene

Phase 1/2 Completed
300 enrolled 23 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡